Solara Active Pharma Sciences Limited (NSE: SOLARA, BSE: 541540) is a Chennai, Tamil Nadu-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹3,225 Cr, it ranks #1,025 by market cap among the 6,197 Indian listed companies on FinBizNet, and #5 of 26 in Pharmaceutical Contract Manufacturing Services. At ₹684.15 (as of 16 Nov 2026), the share price is 11.6% below its 52-week high of ₹774.00 and 62.1% above its 52-week low of ₹422.00. The share price is up 22.1% over one year and up 33.0% over three months.
| Current Price | ₹684.15 |
|---|---|
| Market Cap | ₹3,225 Cr |
| NSE Symbol | SOLARA |
| BSE Code | 541540 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | -0.63% |
| Return on Assets | 2.41% |
| 52-Week Range | ₹422.00 – ₹774.00 |
| 1-Year Price Change | +22.1% |
| 3-Month Price Change | +33.0% |
| Beta (1Y) | 0.1 |
| Dividend Yield | 0.00% |
| Headquarters | Chennai, Tamil Nadu |
| Website | www.solara.co.in |
| Revenue | ₹417 Cr |
|---|---|
| Net Profit | ₹28 Cr |
| Net Margin | 6.8% |
| EPS (Basic) | ₹5.92 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Solara Active Pharma Sciences Limited reported revenue of ₹417 Cr in Q2 FY27, up 33.1% from ₹314 Cr in Q2 FY26 and up 9.4% from ₹382 Cr in Q1 FY27. It posted a net profit of ₹28 Cr for the quarter, against a net loss of ₹10 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹273 Cr (Q4 FY25) to ₹417 Cr (Q2 FY27). The company reported a net loss in 3 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹417 Cr | ₹28 Cr | 6.8% |
| Q1 FY27 | ₹382 Cr | ₹16 Cr | 4.3% |
| Q4 FY26 | ₹387 Cr | ₹10 Cr | 2.5% |
| Q3 FY26 | ₹349 Cr | −₹17 Cr | −5.0% |
| Q2 FY26 | ₹314 Cr | −₹10 Cr | −3.2% |
| Q1 FY26 | ₹319 Cr | ₹11 Cr | 3.3% |
| Q4 FY25 | ₹273 Cr | −₹2 Cr | −0.8% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 41.93% of Solara Active Pharma Sciences Limited's shares as of Sept 2026, against 42.00% in Dec 2025 (−0.07 percentage points). Delivery averaged 42.5% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-retroviral, antibiotic, anticonvulsant, antidepressant, antifibrinolytics, antigout agent, antihelmintic, antihistamine, antihyperlipoproteinemic, antimycotic, antifungal, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antiulcer, antiulcerative, anxiolytic, aprepitant, bile acid analogue, calcimimetic agent, cardiovascular agent, chronic alcoholism, treatment of hyperphosphatemia, hemorrheologic agent, hypercholesterolemia, hypophosphatemic agent, immun
1. Manufacture and Sale of Active Pharma Ingredients-This segment develops, manufactures, and sells active pharmaceutical ingredients. It also provides contract manufacturing and development services.
1. Active Pharmaceutical Ingredient-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Torrent Pharma Ltd. | ₹1,79,494 Cr | 73.6 | 16.98% | ₹4,979 Cr | +30.4% |
| Aether Industries Limited | ₹21,710 Cr | 101.8 | 9.81% | ₹347 Cr | +127.8% |
| Alivus Life Sciences Ltd | ₹17,862 Cr | 31.5 | 18.36% | ₹682 Cr | +64.0% |
| Aarti Pharmalabs Ltd | ₹8,374 Cr | 52.5 | 8.49% | ₹610 Cr | +15.4% |
| Solara Active Pharma Sciences Limited | ₹3,225 Cr | n/m | -0.63% | ₹417 Cr | +22.1% |
| Sai Parenteral's Limited | ₹2,235 Cr | 115.8 | 2.88% | ₹195 Cr | — |
| KRM Ayurveda Limited | ₹521 Cr | 25.9 | 17.54% | ₹32 Cr | — |
| Trident Lifeline Limited | ₹511 Cr | 26 | — | — | +37.6% |
| Infinium Pharmachem Limited | ₹436 Cr | 36.4 | 10.54% | — | +11.7% |
Listed by market capitalisation. Ratios are shown for context only.
Solara Active Pharma Sciences Limited is trading at ₹684.15, with a market capitalisation of ₹3,225 Cr.
Solara Active Pharma Sciences Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Solara Active Pharma Sciences Limited has a return on equity of -0.63%.
Solara Active Pharma Sciences Limited is listed on the NSE under the symbol SOLARA and on the BSE under the scrip code 541540.
Solara Active Pharma Sciences Limited's share price is up 22.1% over one year and up 33.0% over three months. Its 52-week range is ₹422.00 to ₹774.00.
In Q2 FY27, Solara Active Pharma Sciences Limited reported revenue of ₹417 Cr and net profit of ₹28 Cr, with basic EPS of ₹5.92 (consolidated, parsed from the company's exchange filing).
Solara Active Pharma Sciences Limited reported revenue of ₹417 Cr in Q2 FY27, up 33.1% from ₹314 Cr in Q2 FY26 and up 9.4% from ₹382 Cr in Q1 FY27.
Promoters held 41.93% of Solara Active Pharma Sciences Limited's shares as of Sept 2026, against 42.00% in Dec 2025 (−0.07 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.